(주)셀렉스라이프사이언스

News

ILIAS is the Leader of Next-Generation Exosome Therapeutics.

[ENG] 보도자료

ILIAS Biologics appointed a new co-CEO from 1 January 2021

페이지 정보

  • 작성자 : ILIAS Biologics
  • 작성일 : 21-01-05 13:52
  • 조회 : 325회

본문

 

5 Jan 2021


ILIAS Biologics appointed a new co-CEO from 1 January 2021 

 

We are pleased to announce that Taejin Ham is appointed as Chief Executive Officer of ILIAS Biologics effective from 1 January 2021. Taejin joined ILIAS in 2020 as Chief Operating Officer and has since successfully redefined ILIAS's strategy and focus to position the company as a leading biotech in exosome-based therapeutics. Taejin brings over 20 years of business experience in diverse leadership roles at global biopharma companies, Eli Lilly and Celgene. Meanwhile, Dr. Chulhee Choi, the founder and chairman of ILIAS will continue to serve as co-CEO and Chief Scientific Officer and focus on strengthening ILIAS's R&D capability.   

 

For more details, please read the full press release.

(Kor)


개인정보취급방침

닫기

이메일주소무단수집거부

닫기

사이트맵

사이트맵

몬트리올의정서
국내이행법령
사업안내
특정물질 수출입
알림·자료실
민원서비스
닫기